

# Predicting PTSD using the New York Risk Score with genotype data: potential clinical and research opportunities

Joseph A Boscarino<sup>1,2</sup>  
H Lester Kirchner<sup>3,4</sup>  
Stuart N Hoffman<sup>5</sup>  
Porat M Erlich<sup>1,4</sup>

<sup>1</sup>Center for Health Research,  
Geisinger Clinic, Danville,

<sup>2</sup>Department of Psychiatry, Temple  
University School of Medicine,  
Philadelphia, <sup>3</sup>Division of Medicine,  
Geisinger Clinic, Danville,

<sup>4</sup>Department of Medicine, Temple  
University School of Medicine,  
Philadelphia, <sup>5</sup>Department of  
Neurology, Geisinger Clinic, Danville,  
PA, USA

**Background:** We previously developed a post-traumatic stress disorder (PTSD) screening instrument, ie, the New York PTSD Risk Score (NYPRS), that was effective in predicting PTSD. In the present study, we assessed a version of this risk score that also included genetic information.

**Methods:** Utilizing diagnostic testing methods, we hierarchically examined different prediction variables identified in previous NYPRS research, including genetic risk-allele information, to assess lifetime and current PTSD status among a population of trauma-exposed adults.

**Results:** We found that, in predicting lifetime PTSD, the area under the receiver operating characteristic curve (AUC) for the Primary Care PTSD Screen alone was 0.865. When we added psychosocial predictors from the original NYPRS to the model, including depression, sleep disturbance, and a measure of health care access, the AUC increased to 0.902, which was a significant improvement ( $P = 0.0021$ ). When genetic information was added in the form of a count of PTSD risk alleles located within *FKBP5*, *COMT*, *CHRNA5*, and *CRHR1* genetic loci (coded 0–6), the AUC increased to 0.920, which was also a significant improvement ( $P = 0.0178$ ). The results for current PTSD were similar. In the final model for current PTSD with the psychosocial risk factors included, genotype resulted in a prediction weight of 17 for each risk allele present, indicating that a person with six risk alleles or more would receive a PTSD risk score of  $17 \times 6 = 102$ , the highest risk score for any of the predictors studied.

**Conclusion:** Genetic information added to the NYPRS helped improve the accuracy of prediction results for a screening instrument that already had high AUC test results. This improvement was achieved by increasing PTSD prediction specificity. Further research validation is advised.

**Keywords:** post-traumatic stress disorder, psychological trauma, diagnostic screening, test development, genotype, single nucleotide polymorphism

## Introduction

The goal of our original study was to identify brief risk assessment instruments for post-traumatic stress disorder (PTSD). To meet this objective, we used data from several trauma studies, including data related to mental health status, substance misuse, and other psychosocial measures.<sup>1–3</sup> In these studies, PTSD was assessed based on the full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.<sup>4</sup> As discussed, combining these original studies gave a population that included 3298 persons, 270 of whom were PTSD-positive cases.<sup>1–3</sup>

A number of brief PTSD screening tools are currently available. These include the Primary Care PTSD Screen (PCPS), the Short Screening Scale for PTSD, and

Correspondence: Joseph A Boscarino  
Center for Health Research, MC 44-00,  
Geisinger Clinic, 100 N Academy  
Avenue, Danville,  
PA 17822-4400, USA  
Tel +1 570 214 9622  
Fax +1 570 214 9451  
Email jaboscarino@geisinger.edu

the Short PTSD Rating Interview, among others.<sup>5–10</sup> These screeners are relatively short, appear to have reasonable specificity and sensitivity, and are typically focused on core PTSD symptoms.<sup>1</sup>

When developing the original New York PTSD Risk Score (NYPRS), our primary goal was to create a simple screening instrument that was useful in different clinical settings and improved upon current screeners.<sup>1</sup> Our objective was to develop a PTSD assessment tool that could be used in different settings to plan treatment interventions and resource allocations. Consistent with this approach, we examined multiple risk factors that extended beyond single-dimension PTSD screeners in common use.<sup>7</sup> Our original approach was consistent with the method recently used by Marx et al in a study designed to predict combat PTSD among Vietnam veterans.<sup>11</sup> In our current study, we assess the utility of a psychosocial prediction model that also includes genetic risk information.<sup>12</sup>

Previous research regarding traumatic events guided our original study.<sup>13–15</sup> Although research suggests that most persons recover quickly from traumatic experiences,<sup>16</sup> reviews of existing studies suggest that exposure to traumatic events typically results in mental health impairments among a subgroup of individuals.<sup>17,18</sup> Research also suggests that PTSD is not only associated with neuroendocrine and immune system alterations,<sup>19,20</sup> but also with the onset of inflammatory-related health conditions,<sup>21</sup> pointing to the neurobiological foundation of this disorder.<sup>22</sup>

Based on this body of research, the focus of the current study was to assess diagnostic PTSD instruments for use in clinical practice that also incorporated genetic risk information. As previously noted, prediction of the onset and course of PTSD has been difficult.<sup>23,24</sup> Typically, variables related to predisposition, those occurring before the exposure to trauma, and variables occurring after the exposure to trauma are the best predictors of PTSD onset and course.<sup>23,24</sup>

To date, several genetic components for PTSD have been identified that may explain vulnerability to PTSD. These include biologic pathways involving the hypothalamic-pituitary-adrenal axis, locus coeruleus, and noradrenergic and limbic systems.<sup>25–28</sup> In the current study, risk factors for PTSD were assessed among outpatients with a high prevalence of PTSD, ie, patients seen for chronic noncancer pain in a large regional medical center.<sup>29</sup> Chronic noncancer pain is a condition often associated with a history of PTSD.<sup>30</sup>

In this study, we assessed four known genetic markers for PTSD using a cumulative risk allele model, similar to what has been done to predict genetic associations in other

clinical areas.<sup>31</sup> Specifically, we completed diagnostic interviews and collected DNA samples among 412 pain patients to determine if *FKBP5* (rs9470080), *COMT* (rs4680), *CHRNA5* (rs16969968), and *CRHR1* (rs110402) single nucleotide polymorphisms were cumulatively associated with PTSD, after psychosocial predictors from the NYPRS were added to the prediction model.

We previously reported that a count of specific PTSD risk alleles located within *FKBP5*, *COMT*, *CHRNA5*, and *CRHR1* genetic loci (risk allele count range = 0–6, mean count = 2.92, standard deviation = 1.36) was associated with lifetime ( $t[409] = 3.430$ ,  $P = 0.001$ ) and early onset PTSD ( $t[409] = 4.239$ ,  $P = 0.000028$ ).<sup>12</sup> In logistic regression, controlling for demographic factors, personality traits, and exposures to trauma, this risk allele count remained associated with both lifetime (odds ratio = 1.49,  $P = 0.00158$ ) and early-onset PTSD (odds ratio = 2.36,  $P = 0.000093$ ).<sup>12</sup> Similar to other research,<sup>32</sup> our plan was to incorporate this genetic information into our original NYPRS model. Our specific research objective was to determine if a genotype-informed NYPRS model improved the diagnostic performance. If this information improved the accuracy of prediction, it might have future clinical and diagnostic implications.

## Materials and methods

### Conceptual approach

As noted, the research suggests that increased vulnerability to PTSD occurs among those with a history of mental health disorders and previous psychological trauma.<sup>24,33–36</sup> In addition, the psychobiological bases of these syndromes have also become more clear.<sup>22,37</sup> Consequently, we anticipated a number of behavioral-cognitive phenomena to emerge in traumatized persons, including sleep disturbances, substance misuse, and alterations in functional and mental health status.<sup>1,21</sup> Currently, PTSD is known to be associated with outcomes along several causal pathways that encompass cognitive, behavioral, and biological domains.<sup>38</sup> Accordingly, we used a multifactorial approach to guide our original model building, combined with agnostic (ie, atheoretical) examinations of statistical results to develop a new PTSD prediction model.<sup>1</sup> As briefly described below, the original NYPRS enabled the testing of specific models that were conceptually and empirically grounded and included a sample size adequate for data analysis.<sup>1–3,39</sup>

### Development of risk score and statistical analysis

As we have described elsewhere,<sup>1</sup> we used a process of moving candidate variables in and out of prediction models, which

allowed for manipulation of specificity and sensitivity.<sup>40</sup> An initial model was developed using variables thought to be related to PTSD. This model was then extended to include the unique collection of candidate measurements of interest. These variables included mental health status, substance misuse, lifetime and current stress exposures, and community resource measures, among other psychosocial measures.<sup>1–3,39</sup> The goal of this model building was to estimate the area under the receiver operating characteristic curve (AUC), while using the fewest number of parameters.<sup>1</sup>

A nonparametric approach was used to compare the added effects of other variables above the contribution of the base model.<sup>41</sup> The results of the model were then used to construct a “risk score” for PTSD. The properties of the risk scores were examined in terms of sensitivity, specificity, AUC, and by use of a nomogram,<sup>41</sup> which is a graphical tool used to represent the model in terms of standardized weights.<sup>1</sup> These weights are the equivalent of standardized beta coefficients in linear regression, except that the base model coefficient is typically set to a score of 100 for the largest coefficient to aid in scoring.<sup>1</sup> One problem in estimating measures of diagnostic ability using the same dataset in which the model was derived is overestimation.<sup>1</sup> In the current study, this was corrected by estimating a bias-corrected version using a 1000-sample bootstrap procedure to provide a more accurate estimate of the AUC.<sup>42</sup> This procedure is considered superior to cross-validation using a training and validation dataset.<sup>42</sup> In addition to estimating the AUC, we also used Youden’s index,<sup>40</sup> a summary measure of the receiver operating characteristic curve that provides a criterion for choosing a cutoff for which both sensitivity and specificity are maximized.<sup>41,43</sup> As a final step, PTSD genotype information identified in previous research, described below, was added to the prediction model in the form of risk alleles coded 0–6 (see Appendix).<sup>12</sup> The statistical software used in this study included SAS version 9.2 (SAS Institute Inc, Cary, NC, USA),<sup>44</sup> the RMS package in R version 2.15 (R Foundation for Statistical Computing, Vienna, Austria),<sup>45</sup> Stata version 12.1 (Stata Corporation, College Station, TX),<sup>46</sup> and Pepi software version 4.0 (Sagebrush Press, Salt Lake City, UT, USA).<sup>47</sup>

## Use of existing PTSD screeners and other measures

As part of our original study, we reviewed existing PTSD screening instruments currently in clinical use.<sup>7</sup> In the initial New York PTSD Risk Score study,<sup>1</sup> we used two of these screener instruments, ie, the Short Screening Scale for PTSD

and the PCPS.<sup>6,48</sup> In the current study, we present the results only for the PCPS, because this instrument is more widely used than the Short Screening Scale for PTSD and generally produces better prediction results.<sup>1</sup> In addition, based on our previous study, we used core psychosocial measures identified in our earlier NYPRS research. This included a two-item measure of lifetime symptoms of depression, ie, the Patient Health Questionnaire-2.<sup>1</sup> Other assessments included a measure of current health care access and reported sleep disturbance.<sup>1</sup> For the lifetime PTSD model, we used a measure of lifetime sleeping problems. For current PTSD, we used a measure of sleeping problems in the past year. Altogether we examined more than 100 potential diagnostic predictors, however only a few proved significant in distinguishing cases from noncases using the diagnostic testing approach described.<sup>1</sup> Access to health care was assessed by a question related to having a regular doctor or access to health care. Difficulty sleeping was assessed by a question about ever experiencing sleeping problems in the past for two weeks or more or in the past 12 months. A measure of lifetime trauma exposure, which was included in previous NYPRS models,<sup>1</sup> was dropped from our analyses in the current study due to a lack of statistical significance. This trauma measure was based on reported lifetime exposure to traumatic events, including being in a serious accident, being physically/sexually assaulted, or being in a war zone, with a history of 4+ lifetime events defined as high exposure to trauma. The specific measures used in the final prediction models, including genotype information, are included in the study Appendix.

## PTSD measure

Study interviewers administered diagnostic surveys using instruments deployed in past PTSD research, including the National Women’s Study and the World Trade Center Study in New York.<sup>24,49–52</sup> To have PTSD in the current study, patients had to meet the full diagnostic criteria for lifetime PTSD, known as the “A through F” criteria.<sup>24</sup> These criteria include experiencing intense fear (criterion A), re-experiencing the event (criterion B), avoidance of stimuli associated with the event (criterion C), experiencing increased arousal (criterion D), experiencing symptoms for more than a month (criterion E), and experiencing psychological distress or impairment (criterion F). In the present study, we assessed both lifetime and current PTSD, with the latter defined as meeting the full DSM-IV PTSD criteria in the past 12 months. Data related to the validity of this PTSD measure have been previously published.<sup>24,49–53</sup>

## Subjects

The study subjects were adult outpatients (18+ years of age) with chronic noncancer pain treated in a large health care system.<sup>29,54</sup> Patients with chronic noncancer pain typically have a high prevalence of PTSD.<sup>55,56</sup> The mean age of the patients studied was  $55 \pm 13.4$  years and the prevalence of lifetime PTSD was 14.3% (95% confidence interval [CI] 11.1%–18.1%). The study sample was randomly selected from a population of chronic pain patients identified by query of electronic health records held at the Geisinger Clinic, an integrated health system that serves residents of 40 central and northeastern Pennsylvania counties.<sup>29</sup> Geisinger's ambulatory clinics have used the Epic outpatient electronic health record system (Epic System Corporation, Verona, WI, USA) since 2001. With patient consent, trained and supervised interviewers administered structured diagnostic telephone interviews from August, 2007 through November, 2008. This study was approved by the institutional review board at Geisinger Clinic.

## DNA collection and genotyping

Following the diagnostic interviews, buccal swab kits were mailed to consenting adults. Altogether, 414 returned the buccal swab kit with adequate DNA for the current analyses. Two subjects were identified as non-Caucasian and were not included in the current study to avoid problems due to population stratification and the different allele frequencies found among different ethnic groups. The candidate genes studied and corresponding single nucleotide polymorphisms were: catechol-O-methyltransferase (*COMT*; rs4680), FK506 binding protein 51 (*FKBP5*; rs9470080), cholinergic receptor, nicotinic, alpha 5 (*CHRNA5*; rs16969968) and corticotropin-releasing hormone receptor-1 (*CRHRI*; rs110402). These four single nucleotide polymorphisms were found to be significant predictors of PTSD in the past.<sup>12</sup> The targeted single nucleotide polymorphisms were originally part of a broader behavioral health study related to the genetics of pain, stress, and addiction reported elsewhere.<sup>54,57,58</sup> The *COMT* gene is associated with anxiety disorders, psychosis, depression, and other conditions involving regulation of the catecholamine pathway and has been associated with PTSD. The *FKBP5* gene regulates sensitivity of the glucocorticoid receptor, is functionally involved in hypothalamic-pituitary-adrenal axis activity, and has also been associated with PTSD in several studies.<sup>59–61</sup> The *CHRNA* gene cluster, which encodes components of the nicotinic acetylcholine receptor, is associated with nicotine dependence and cigarette smoking,<sup>62,63</sup> substance misuse,<sup>54</sup> and, more recently, PTSD.<sup>12,25</sup> The *CRHRI* gene is

associated with a polypeptide hormone and neurotransmitters involved in corticotropin-releasing hormone activity linked to the mammalian stress response.<sup>22</sup> Studies suggest this gene regulates function of the hypothalamic-pituitary-adrenal axis and is associated with the impact of exposure to stress and onset of PTSD.<sup>61,64,65</sup> Combined, these four genetic loci appear to be vital in regulation of mammalian fear circuitry and are also likely to interact with other key biologic pathways, including inflammatory ones.<sup>22,66</sup>

Genotyping was performed on a 7500 real-time polymerase chain reaction platform (Applied BioSystems, Foster City, CA, USA), using TaqMan kits following the manufacturer's protocols. Quality control measures included visual inspection of allelic discrimination plots, monitoring concordance of cross-plated duplicate pairs, monitoring the overall call rate, and monitoring agreement with Hardy-Weinberg expectations.<sup>67</sup>

## Results

The demographic profile of the study subjects shows that 68.8% were female, 66.2% were 40–64 years of age, 62.0% were married, 49.6% had a high school diploma or less education, and 42.1% had an annual household income of \$30,000 or less, as shown in Table 1. Further, 38.9% met criteria for lifetime major depressive disorder and 21.2% had a history of high lifetime exposure to traumatic events (ie, exposed to 4+ traumatic life events). Altogether, 65.7% reported ever having difficulty sleeping for two weeks or more and 1.9% reported that they did not have regular access to a medical doctor or health care services. Finally, as shown in Table 1, in this study population, the prevalence of lifetime PTSD was 14.3% (95% CI 11.1–18.1) and the prevalence of current PTSD was 10.7% (95% CI 7.9–14.1, Table 1). Bivariate analysis suggested that PTSD (both lifetime and current) was most strongly associated with high lifetime trauma exposure, history of major depression, and history of reported sleep problems ( $P < 0.001$ ).

The results for lifetime and current PTSD are shown in Table 2. As can be seen, the PCPS used alone had a sensitivity of 94.9% and a specificity of 78.1% in predicting lifetime PTSD, resulting in an AUC of 0.865 (95% CI 0.822–0.908). Adding the psychosocial predictors from the original NYPRS, including lifetime sleep disturbance, symptoms of depression, and access to health care, resulted in a sensitivity of 94.9% and a specificity of 78.7%, with a corresponding AUC of 0.902 (95% CI 0.873–0.930, bias corrected AUC = 0.889). This represents a significant improvement in the prediction model over the base model that included only the

**Table 1** Patient variables by PTSD status (n = 412)

Study variables	% total (n)	Lifetime PTSD*			Current PTSD**		
		% yes (n)	% no (n)	P value	% yes (n)	% no (n)	P value
Gender							
Male	31.2 (128)	10.2 (13)	89.8 (115)	0.103	7.0 (9)	93.0 (119)	0.105
Female	68.8 (283)	16.3 (46)	83.7 (237)		12.4 (35)	87.6 (248)	
Age, years							
18–39	8.5 (35)	22.9 (8)	77.1 (27)	0.021	20.0 (7)	80.0 (28)	0.051
40–64	66.2 (272)	16.2 (44)	83.8 (228)		11.4 (32)	88.6 (241)	
65+	25.3 (104)	6.7 (7)	93.3 (97)		5.8 (6)	94.2 (98)	
Married							
No	38.0 (156)	19.9 (31)	80.1 (125)	0.013	14.1 (22)	85.9 (134)	0.081
Yes	62.0 (255)	11.0 (28)	89.0 (227)		8.6 (22)	91.4 (233)	
High school or less education							
No	50.4 (207)	14.5 (30)	85.5 (213)	0.936	9.2 (19)	90.8 (188)	0.313
Yes	49.6 (204)	14.2 (29)	85.8 (216)		12.3 (25)	87.7 (179)	
Income less than \$30,000							
No	57.9 (238)	11.3 (27)	88.7 (211)	0.041	7.6 (18)	92.4 (220)	0.016
Yes	42.1 (173)	18.5 (32)	81.5 (141)		15.0 (26)	85.0 (147)	
Limited access to health care							
No	98.1 (403)	14.4 (58)	85.6 (345)	0.880	10.7 (43)	89.3 (360)	0.868
Yes	1.9 (8)	12.5 (1)	87.5 (7)		12.5 (1)	87.5 (7)	
High trauma exposure, ever							
No	78.8 (324)	10.8 (35)	89.2 (289)	<0.001	8.0 (26)	92.0 (298)	<0.001
Yes	21.2 (87)	27.6 (24)	73.4 (63)		20.7 (18)	79.3 (69)	
Major depression, ever							
No	61.1 (251)	2.0 (5)	98.0 (246)	<0.001	1.6 (4)	98.4 (247)	<0.001
Yes	38.9 (160)	33.8 (54)	66.2 (106)		25.0 (40)	75.0 (120)	
Sleep problems, ever							
No	34.3 (141)	2.1 (3)	97.9 (138)	<0.001	0.7 (1)	99.3 (140)	<0.001
Yes	65.7 (270)	20.7 (56)	79.3 (214)		15.9 (43)	84.1 (227)	

**Notes:** \*Lifetime PTSD = 14.3% (95% confidence interval 11.1–18.1); \*\*current PTSD = 10.7% (95% confidence interval 7.9–14.1).

**Abbreviation:** PTSD, post-traumatic stress disorder.

PCPS ( $P < 0.0021$ ). Adding genotype resulted in a sensitivity of 94.9% and a specificity of 81.5%, with an AUC of 0.920 (95% CI 0.897–0.951, bias corrected AUC = 0.901). This also represents a significant improvement over the previous model that included the PCPS and the original NYPRS factors ( $P = 0.0178$ ).

In predicting current PTSD, the PCPS alone had a sensitivity of 95.4% and a specificity of 95.4%, resulting in an

AUC of 0.954 (95% CI 0.916–0.992). Adding key predictors from the original NYPRS, including sleep disturbance, depression symptoms, and access to health care, resulted in a sensitivity of 100.0% and a specificity of 93.2%, with an AUC of 0.982 (95% CI 0.972–0.992, bias corrected AUC = 0.975). This represents a nonsignificant improvement in the prediction model over the base model that included only the PCPS ( $P < 0.0674$ ). Next, adding genotype to the prediction,

**Table 2** Results using NYPRS prediction model with genotype added (n = 412)

	Cutoff score	% specificity	% sensitivity	PV+	PV–	AUC	AUC 95% CI	P value
<b>Prediction model used: lifetime PTSD</b>								
PCPS only	100	78.1	94.9	42.2	98.9	0.865	0.822–0.908	–
PCPS + NYPRS	166	78.7	94.9	42.8	98.9	0.902	0.873–0.930	0.0021
PCPS + NYPRS + genotype	219	81.5	94.9	46.4	99.0	0.920	0.897–0.951	0.0178
<b>Prediction model used: current PTSD</b>								
PCPS only	100	95.4	95.4	71.2	99.4	0.954	0.916–0.992	–
PCPS + NYPRS	192	93.2	100.0	63.8	100.0	0.982	0.972–0.992	0.0674
PCPS + NYPRS + genotype	215	95.6	100.0	73.3	100.0	0.989	0.981–0.997	0.0194

**Abbreviations:** NYPRS, New York PTSD Risk Score; AUC, area under receiver operating characteristic curve; PV+, predictive value of positive test; PV–, predictive value of negative test; PCPS, Primary Care PTSD Screener.



results in a sensitivity of 100.0% and a specificity of 95.6%, with an AUC of 0.989 (95% CI 0.981–0.997, bias corrected AUC = 0.984). This represents a significant improvement over the previous model that included the PCPS and the original NYPRS predictors ( $P = 0.0194$ ).

Table 3 shows the PTSD risk score results in the form of regression-derived weights used to generate the classification results shown in Table 2. As seen, for lifetime PTSD, a positive score on the PCPS (ie, three or more positive items) is given a base score of 100 (otherwise 0) and the psychosocial measures are given weights relative to these results. These weights are then used to calculate a PTSD risk score. The last row of Table 3 shows the cutoff scores for a lifetime PTSD classification based on these risk score weights, ie, 100 for PCPS used alone, 166 for PCPS + NYPRS factors, and 219 for PCPS + NYPRS + genotype.

Examination of the specific weights for the lifetime model is informative. In the final lifetime PTSD model, a weight of 100 is given for screening positive on the PCPS. However, when combined with the NYPRS factors, a weight of 29 is given for having one symptom of depression and a weight

of 40 is given for having two symptoms of depression (having no symptoms results in a weight of 0). Having a history of lifetime sleep disturbance, with a positive PCPS screen, results in a weight of 35, and not having a regular health care provider or access to health results in a weight of 37. As seen, in the final model with the PCPS and NYPRS factors, genotype results in a prediction weight of 14 for each risk allele present. Thus, a person with six risk alleles or more would receive a PTSD score of  $14 \times 6 = 84$ , the second highest score.

For current PTSD, the results are similar. Based on prediction results, a weight of 100 was given for the PCPS used alone, 192 for the PCPS + NYPRS factors, and 215 for the PCPS + NYPRS factors + genotype. Examination of the specific weights for the current PTSD prediction is also informative. In the final model, a weight of 100 is given for screening positive on the PCPS. However, when combined with the NYPRS factors, a weight of 96 is now given to the PCPS, 53 is given for having one depression symptom, and a weight of 24 is given for having two depression symptoms (no depression symptoms = 0). In addition, having current sleep disturbance, with a positive PCPS screen together with other NYPRS factors included, results in a weight of 100 for sleep disturbance, and not having a regular health care provider results in a weight of 72 (Table 3). As seen, in the final model with the PCPS and the psychosocial risk factors from the NYPRS, the genotype score results in a prediction weight of 17 for each risk allele present. Thus, a person with six risk alleles or more would receive a PTSD score of  $17 \times 6 = 102$ , the highest score for any of the predictors assessed.

Table 4 shows the classification improvements that are achieved by adding genotype risk information to the NYPRS prediction model. As can be seen, for lifetime PTSD, improvement in prediction is achieved by increased specificity. In the NYPRS model with the PCPS, 10 cases were reclassified as noncases when genotype was added to the model ( $75 - 65 = 10$ ). For current PTSD, the results were similar, with a small but significant ( $P = 0.0194$ ) improvement in prediction specificity detected ( $25 - 16 = 9$ ). It is important to note that Pearson  $r$  correlations suggested that the genotype risk scores used were not associated with NYPRS measures ( $P > 0.50$ ), indicating that the genotype assessed tends to add unique prediction information to the NYPRS measure.

Finally, using cross-tabular analyses, we assessed whether risk allele count (coded 0–6) was associated with being in the high trauma exposure category (coded yes = 1, no = 0) and found that these were not associated ( $\chi^2 = 5.97$ ,  $df = 6$ ,

**Table 3** Primary Care PTSD Screener and NYPRS weights without and with genotype risk information added

	PCPS only	PCPS + NYPRS	PCPS + NYPRS + genotype
<b>Predictor variables*: lifetime PTSD</b>			
Positive PCPS results	100	100	100
Psychosocial measures from NYPRS			
PHQ-2 = one symptom	–	29	33
PHQ-2 = two symptoms	–	40	50
Sleep disturbance (lifetime)	–	35	33
No regular health care	–	37	30
Genotype			
Risk allele score (0–6)	–	–	14
PTSD cutoff score	100	166	219
<b>Predictor variables*: current PTSD</b>			
Positive PCPS results	100	96	68
Psychosocial measures from NYPRS			
PHQ-2 = one symptom	–	53	38
PHQ-2 = two symptom	–	24	25
Sleep disturbance (current)	–	100	75
No regular health care	–	72	51
Genotype			
Risk allele score (0–6)	–	–	17
PTSD cutoff score	100	192	215

**Notes:** \*PCPS with three positive items results in a score = 100, otherwise = 0 for lifetime PTSD for all prediction models. For current PTSD, a positive PCPS (ie, three items positive) results in a score of 100, 96, and 68, respectively, for the PCPS used alone, PCPS + NYPRS, and the PCPS + NYPRS + genotype, otherwise = 0.

**Abbreviations:** PHQ-2, Patient Health Questionnaire, 2-item version; PCPS, Primary Care PTSD Screener; PTSD, post-traumatic stress disorder; NYPRS, New York PTSD Risk Score.

$P = 0.427$ , linear trend  $P = 0.658$ ). Next, we cross-tabulated the allele count by PTSD status and found that this was significant ( $\chi^2 = 12.93$ ,  $df = 6$ ,  $P = 0.044$ , linear trend  $P = 0.001$ ). Close examination of allele count by PTSD status suggested that a lower risk allele count was protective against onset of PTSD, given that the prevalence of PTSD among those with fewer than two risk alleles was very low (0%–4%) for both lifetime and current PTSD. Conversely, the prevalence of PTSD for those with 4+ risk alleles was typically 20% or higher.<sup>12</sup>

## Discussion

We examined different clinical domains to evaluate prediction models that could be useful in predicting PTSD. Our overall goal was to develop a better PTSD prediction tool that was effective and could guide clinical interventions in different settings.<sup>1</sup> As suggested, based on extensive previous investigations, several prediction domains were identified, including core PTSD symptoms and psychosocial risk factors from the original NYPRS measure. Overall, the NYPRS alone also appeared to work very well in the current study. However, adding information on genotype risk to the NYPRS improved the prediction results.

**Table 4** NYPRS classification without and with genotype information

		Gold standard		
		PTSD	Non-PTSD	Total
<b>NYPRS model without genotype information – lifetime PTSD</b>				
NYPRS $\geq$ 166 (Table 3)	PTSD	56	75	131
	Non-PTSD	3	277	280
	Total	59	352	411
Sensitivity = (56/59) = 94.9%; specificity = (277/352) = 78.7%				
<b>NYPRS model with genotype information – lifetime PTSD</b>				
NYPRS $\geq$ 219 (Table 3)	PTSD	56	65 ↓	121
	Non-PTSD	3	287	290
	Total	59	352	411
Sensitivity = (56/59) = 94.9%; specificity = (287/352) = 81.5%				
<b>NYPRS model without genotype information – current PTSD</b>				
NYPRS $\geq$ 192 (Table 3)	PTSD	44	25	69
	Non-PTSD	0	342	342
	Total	44	367	411
Sensitivity = (44/44) = 100.0%; specificity = (342/367) = 93.2%				
<b>NYPRS model with genotype information – current PTSD</b>				
NYPRS $\geq$ 215 (Table 3)	PTSD	44	16 ↓	60
	Non-PTSD	0	351	351
	Total	44	367	411
Sensitivity = (44/44) = 100.0%; specificity = (351/367) = 95.6%				

**Abbreviations:** NYPRS, New York PTSD Risk Score; PTSD, post-traumatic stress disorder.

Use of PTSD screeners in different health care settings has increased over the years.<sup>1</sup> Currently, the Department of Veterans Affairs and the Department of Defense are routinely using the PCPS in clinical practice to assess veterans and active duty personnel.<sup>68</sup> As has been noted, use of the NYPRS in clinical practice would likely require about 5 minutes or less for administration in most settings.<sup>1</sup> Given our current findings, clinicians might consider collecting genotype information in the future to confirm positive screening results, if further research supports our current findings. As shown, this genetic information appears to increase diagnostic specificity, which may be important before initiating treatment interventions. While this diagnostic improvement was small and more work needs to be done, as Table 2 shows, there was about a 10% improvement in the positive predictive value of the NYPRS when genotype was added to the prediction model. As noted, in the current PTSD model, with the PCPS and NYPRS psychosocial factors included, genotype results in a prediction weight of 17 for each PTSD risk allele present. Therefore, a person with six risk alleles or more would receive a PTSD score of  $17 \times 6 = 102$ , which is a relatively high prediction score. Noteworthy is that the prevalence of PTSD in our study sample was relatively low (<15%). For example, if the prevalence of current PTSD was closer to 20%, the predictive value of a positive test would be greater than 80%. Given the increasing convenience of genotyping and its decreasing cost, the NYPRS administered by a primary care provider with genotyping may be cost-effective in the future. This might be true following large-scale traumatic events or in more remote geographic regions where access to providers of mental health care is limited.

The current study has several strengths and limitations. A major strength was that our original psychometric validation study involved a large survey population and three validation studies, which included a total combined sample of 3298 subjects.<sup>1</sup> We also assessed a broad range of psychological and interpersonal risk factors using standardized instruments and medical testing methods in our original study.<sup>1</sup> Another strength of the study was that the interviewer neither knew the status of the PCPS screener nor any details of the PTSD interview for the patient. These data were coded at the end of the interview by study analysts. Thus, interviewer bias was limited. Potential study limitations include omission of individuals without a telephone and those who were institutionalized. Moreover, nonresponse bias could have affected our survey results.<sup>1</sup> In addition, in the current study, we did not predict future PTSD, which is often difficult.<sup>39</sup> Nevertheless, we have conducted prospective predictions of

PTSD using the NYPRS in the past and these models have worked well.<sup>3</sup> However, these prospective PTSD predictions did not include genetic information. This research is planned as part of a future study. Also, the study sample size in the current analysis was limited ( $n = 412$ ) and drawn from a single region of the US, ie, central Pennsylvania. The current study was also comprised of Caucasians of European lineage. All these factors may have biased our findings. Finally, the genetic variants studied were limited to four candidate single nucleotide polymorphisms and, while statistically significant, their contribution to the NYPRS model was modest (eg, about 3% improvement in specificity). Given the complexity of behavioral genetics,<sup>69</sup> clearly more work is needed before clinical implementation can be recommended.

Despite these limitations, our study suggests that a screening instrument, the NYPRS (Genetic Version) may have utility in PTSD screening in the future. This screening instrument has good sensitivity and specificity. Adding genetic information appeared to improve PTSD specificity and, thus, reduced the inaccuracy of this screening. It is also noted that the genotype count assessed and the NYPRS score results without the genotype were not associated, based on examination of Pearson  $r$  correlations ( $P > 0.5$ ). This suggests that the genotype measure adds unique information on prediction. Also, as noted above, our analyses indicated that individuals with fewer than two PTSD risk alleles appear resilient to PTSD, regardless of exposure to trauma, given that the risk allele count examined was not associated with exposure to trauma but was linearly associated with PTSD.<sup>12</sup> The fact that the genotype added anything at all to our PTSD prediction model, given the impact of the PCPS and the NYPRS alone, we think suggests that further research is warranted.

## Acknowledgment

Supported in part by grants from the National Institute of Mental Health (R21-MH-086317) and the Geisinger Clinic Research Fund (TRA-015, to Boscarino).

## Disclosure

The preliminary results of this study were presented at the 31st Annual Meeting of the Anxiety Disorders Association of America, New Orleans, LA, on March 26, 2011. Otherwise, the authors report no conflicts of interest in this work.

## References

- Boscarino JA, Kirchner HL, Hoffman SN, Sartorius J, Adams RE, Figley CR. A brief screening tool for assessing psychological trauma in clinical practice: development and validation of the New York PTSD Risk Score. *Gen Hosp Psychiatry*. 2011;33:489–500.
- Boscarino JA, Kirchner HL, Hoffman SN, Sartorius J, Adams RE, Figley CR. The New York PTSD risk score for assessment of psychological trauma: male and female versions. *Psychiatry Res*. 2012;200:827–834.
- Boscarino JA, Kirchner HL, Hoffman SN, Sartorius J, Adams RE, Figley CR. Predicting future PTSD using a modified New York Risk Score: implications for patient screening and management. *Minerva Psichiatr*. 2012;53:47–59.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision*. Arlington, VA: American Psychiatric Publishing; 2000.
- Bliese PD, Wright KM, Adler AB, Cabrera O, Castro CA, Hoge CW. Validating the Primary Care Posttraumatic Stress Disorder Screen and the Posttraumatic Stress Disorder Checklist with soldiers returning from combat. *J Consult Clin Psychol*. 2008;76:272–281.
- Breslau N, Peterson EL, Kessler RC, Schultz LR. Short Screening Scale for DSM-IV Posttraumatic Stress Disorder. *Am J Psychiatry*. 1999;156:908–911.
- Brewin CR. Systematic review of screening instruments for adults at risk of PTSD. *J Trauma Stress*. 2005;18:53–62.
- Lang AJ, Stein MB. An abbreviated PTSD Checklist for use as a screening instrument in primary care. *Behav Res Ther*. 2005;43:585–594.
- Norris FH, Donahue SA, Felton CJ, Watson PJ, Hamblen JL, Marshall RD. A psychometric analysis of Project Liberty's adult enhanced services referral tool. *Psychiatr Serv*. 2006;57:1328–1334.
- Winston FK, Kassam-Adams N, Garcia-Espana F, Ittenbach R, Cnaan A. Screening for risk of persistent posttraumatic stress in injured children and their parents. *JAMA*. 2003;290:643–649.
- Marx BP, Humphreys KL, Weathers FW, et al. Development and initial validation of a statistical prediction instrument for assessing combat-related posttraumatic stress disorder. *J Nerv Ment Dis*. 2008;196:605–611.
- Boscarino JA, Erlich PM, Hoffman SN, Zhang X. Higher FKBP5, COMT, CHRNA5, and CRHR1 allele burdens are associated with PTSD and interact with trauma exposure: implications for neuropsychiatric research and treatment. *Neuropsychiatr Dis Treat*. 2012;8:131–139.
- Freedy JR, Kilpatrick DG, Resnick HS. Natural disasters and mental health: theory, assessment, and intervention. *J Soc Behav Pers*. 1993;8:49–103.
- Fullerton CS, Ursano RJ, editors. *Posttraumatic Stress Disorder: Acute and Long-Term Responses to Trauma and Disaster*. Washington, DC: American Psychiatric Press Inc; 1997.
- Gleser GC, Green BL, Winget CN. *Prolonged Psychosocial Effects of Disaster: A Study of Buffalo Creek*. New York, NY: Academic Press; 1981.
- McFarlane AC. The aetiology of post-traumatic morbidity: predisposing, precipitating and perpetuating factors. *Br J Psychiatry*. 1989;154:221–228.
- Norris FH, Friedman MJ, Watson PJ. 60,000 disaster victims speak: Part II. Summary and implications of the disaster mental health research. *Psychiatry*. 2002;65:240–260.
- Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. *J Consult Clin Psychol*. 2000;68:748–766.
- Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. *Ann NY Acad Sci*. 2006;1071:137–166.
- Vasterling JJ, Brewin CR, editors. *Neuropsychology of PTSD: Biological, Cognitive, and Clinical Perspectives*. New York, NY: Guilford Press; 2005.
- Schnurr PP, Green BL, editors. *Trauma and Health: Physical Health Consequences of Exposure to Extreme Stress*. Washington, DC: American Psychological Association; 2004.
- Boscarino JA, Figley CR. Understanding the neurobiology of fear conditioning and emergence of posttraumatic stress disorder psychobiology: commentary on Blanchard et al. *J Nerv Ment Dis*. 2012;200:740–744.



23. Adams RE, Boscarino JA. A structural equation model of perievent panic and posttraumatic stress disorder after a community disaster. *J Trauma Stress*. 2011;24:61–69.
24. Boscarino JA, Adams RE. PTSD onset and course following the World Trade Center disaster: findings and implications for future research. *Soc Psychiatry Psychiatr Epidemiol*. 2009;44:887–898.
25. Boscarino JA, Erlich PM, Hoffman SN, Rukstalis M, Stewart WF. Association of FKBP5, COMT and CHRNA5 polymorphisms with PTSD among outpatients at risk for PTSD. *Psychiatry Res*. 2011;188:173–174.
26. Broekman BF, Olff M, Boer F. The genetic background to PTSD. *Neurosci Biobehav Rev*. 2007;31:348–362.
27. Dannlowski U, Stuhrmann A, Beutelmann V, et al. Limbic scars: long-term consequences of childhood maltreatment revealed by functional and structural magnetic resonance imaging. *Biol Psychiatry*. 2012;71:286–293.
28. Rauch SL, Drevets WC. Neuroimaging and neuroanatomy of stress-induced and fear circuitry disorders. In: Andrews G, Charney DS, Sirovatka PJ, Regier DA, editors. *Stress-Induced and Fear Circuitry Disorders: Refining the Research Agenda for DSM-V*. Washington, DC: American Psychiatric Association; 2009.
29. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. *Addiction*. 2010;105:1776–1782.
30. McFarlane AC. The long-term costs of traumatic stress: intertwined physical and psychological consequences. *World Psychiatry*. 2010;9:3–10.
31. Still CD, Wood GC, Chu X, et al. High allelic burden of four obesity SNPs is associated with poorer weight loss outcomes following gastric bypass surgery. *Obesity*. 2011;19:1676–1683.
32. Ding K, Bailey KR, Kullo IJ. Genotype-informed estimation of risk of coronary heart disease based on genome-wide association data linked to the electronic medical record. *BMC Cardiovasc Disord*. 2011;11:66.
33. Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. *Arch Gen Psychiatry*. 1998;55:626–632.
34. Breslau N, Chilcoat HD, Kessler RC, Davis GC. Previous exposure to trauma and PTSD effects of subsequent trauma: results from the Detroit Area Survey of Trauma. *Am J Psychiatry*. 1999;156:902–907.
35. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1995;52:1048–1060.
36. Yehuda R, editor. *Risk Factors for Posttraumatic Stress Disorder*. Washington, DC: American Psychiatric Press Inc; 1999.
37. Ursano RJ, Goldenberg M, Zhang L, et al. Posttraumatic stress disorder and traumatic stress: from bench to bedside, from war to disaster. *Ann NY Acad Sci*. 2010;1208:72–81.
38. Boscarino JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. *Ann NY Acad Sci*. 2004;1032:141–153.
39. Boscarino JA, Kirchner HL, Hoffman SN, Sartorius J. Use of the New York PTSD risk score to predict PTSD: current and future research efforts. *Gen Hosp Psychiatry*. 2012;34:317–319.
40. Pepe MS. *The Statistical Evaluation of Medical Tests for Classification and Prediction*. New York, NY: Oxford University Press; 2003.
41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44:837–845.
42. Harrell FE. *Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis*. New York, NY: Springer; 2001.
43. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. *Biom J*. 2005;47:458–472.
44. SAS Institute Inc. *SAS Version 9.2*. Cary, NC: SAS Institute Inc; 2010.
45. R Development Core Team. Vienna, Austria: R Foundation for Statistical Computing; 2012. Available from: <http://www.R-project.org>. Accessed March 19, 2013.
46. Stata Corporation. Stata version 12.1. College Station, TX: Stata Corporation; 2012.
47. Abramson JH, Gahlinger PM. *Computer Programs for Epidemiologists. PEPI, Version 4.0*. Salt Lake City, UT: Sagebrush Press; 2001.
48. Ouimette P, Wade M, Prins A, Schohn M. Identifying PTSD in primary care: comparison of the Primary Care-PTSD Screen (PC-PTSD) and the General Health Questionnaire-12 (GHQ). *J Anxiety Disord*. 2008;22:337–343.
49. Boscarino JA, Adams RE, Foa EB, Landrigan PJ. A propensity score analysis of brief worksite crisis interventions after the World Trade Center disaster: implications for intervention and research. *Med Care*. 2006;44:454–462.
50. Galea S, Ahern J, Resnick H, et al. Psychological sequelae of the September 11 terrorist attacks in New York City. *N Engl J Med*. 2002;346:982–987.
51. Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. *J Consult Clin Psychol*. 1993;61:984–991.
52. Wilson JP, Keane TM. *Assessing Psychological Trauma and PTSD*, 2nd ed. New York, NY: The Guilford Press; 2004.
53. Kilpatrick DG, Resnick HS, Freedy JR, et al. The posttraumatic stress disorder field trial: Evaluation of the PTSD construct – criteria A through E. In: Widiger T, Frances A, Pincus H, et al, editors. *DSM-IV Sourcebook*. Washington, DC: American Psychiatric Association Press; 1998;4.
54. Erlich PM, Hoffman SN, Rukstalis M, et al. Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are associated with nicotine and opioid dependence severity. *Hum Genet*. 2010;128:491–499.
55. Beck JG, Clapp JD. A different kind of co-morbidity: understanding posttraumatic stress disorder and chronic pain. *Psychol Trauma*. 2011;3:101–108.
56. Phifer J, Skelton K, Weiss T, et al. Pain symptomatology and pain medication use in civilian PTSD. *Pain*. 2011;152:2233–2240.
57. Boscarino JA, Erlich PM, Hoffman SN, Rukstalis MR, Han JJ, Stewart WF. Polymorphism in OPRM1 genetic locus is associated with opioid dependence, alcohol dependence, cocaine use and amphetamine use among chronic pain patients. Presented at the NIDA/NIAAA Satellite Meeting on the Genetics and Epigenetics of Substance Abuse, World Congress on Psychiatric Genetics, Washington, DC, September 9, 2011.
58. Boscarino J, Hoffman S, Gerhard G, et al. Generalized anxiety and depression among chronic pain patients on opioid therapy are associated with higher pain impairment, increased service utilization and poorer health status. *Clin Med Res*. 2012;10:183.
59. Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. *JAMA*. 2008;299:1291–1305.
60. Koenen KC. Genetics of posttraumatic stress disorder: Review and recommendations for future studies. *J Trauma Stress*. 2007;20:737–750.
61. Gillespie CF, Phifer J, Bradley B, Ressler KJ. Risk and resilience: genetic and environmental influences on development of the stress response. *Depress Anxiety*. 2009;26:984–992.
62. Spitz MR, Amos CI, Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. *J Natl Cancer Inst*. 2008;100:1552–1556.
63. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature*. 2008;452:638–642.
64. von Wolff G, Avrabos C, Stepan J, et al. Voltage-sensitive dye imaging demonstrates an enhancing effect of corticotropin-releasing hormone on neuronal activity propagation through the hippocampal formation. *J Psychiatr Res*. 2011;45:256–261.

65. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. *Biol Psychiatry*. 2009;66:681–685.
66. Boscarino JA. Psychoneuroimmunology of trauma. In: Figley CR, editor. *Encyclopedia of Trauma*. Thousand Oaks, CA: Sage Publications; 2012:497–501.
67. Strachan T, Read A. *Human Molecular Genetics*, 4th ed. New York, NY: Garland Science; 2011.
68. Calhoun PS, McDonald SD, Guerra VS, et al. Clinical utility of the Primary Care PTSD Screen among US veterans who served since September 11, 2001. *Psychiatry Res*. 2010;178:330–335.
69. Boscarino JA. Genetic epidemiology. In: Figley CR, editor. *Encyclopedia of Trauma*. Thousand Oaks, CA: Sage Publications; 2012:277–280.

## Appendix

### New York PTSD Risk Score (Genetic Version)

**Primary Care PTSD Screener** (asked for lifetime and previous 12 months)

1. Have you had repeated bad dreams or nightmares or had disturbing or unpleasant memories, thoughts, or images that kept coming into your mind whether you wanted to think of them or not?
2. Have you deliberately tried hard not to think about something that happened to you or went out of your way to avoid certain places or activities that might remind you of something that happened in the past?
3. Have you felt you had to stay on guard much of the time or unexpected noises startled you more than usual?
4. Have you felt cut off from other people, or found it difficult to feel close to other people, or you could not feel things anymore or you had much less emotion than you used to have?

**Symptoms of depression** (asked for lifetime)

5. Have you ever had a period of two weeks or longer when you were feeling depressed or down most of the day or nearly every day?
6. Have you ever had a period of two weeks or longer when you were uninterested in most things or unable to enjoy things you used to do?

**Sleep disturbance** (asked for lifetime and previous 12 months)

7. Have you had difficulty falling asleep or staying asleep?

**Source of health care/regular doctor** (asked for previous 12 months)

8. Do you have a regular doctor or a usual source of care that you can go to for routine medical care?
9. Count of PTSD risk-alleles located within *FKBP5*, *COMT*, *CHRNA5*, and *CRHR1* genetic loci (coded 0–6, see Table A).

**Table A** Single nucleotide polymorphisms in NYPRS risk allele prediction model

SNP	Gene	Chromosome (map location)	MAF (minor/common)	Functional annotation	PTSD risk allele counted
<b>Marker specifications (NCBI build 37.1)</b>					
rs16969968*	<i>CHRNA5</i>	15 (78882925)	35.0% (A/G)	Missense (D↔N)	A
rs9470080**	<i>FKBP5</i>	6 (35646435)	33.0% (T/C)	Intron	T
rs4680*	<i>COMT</i>	22 (19951271)	49.5% (G/A)	Missense (V↔M)	A
rs110402*	<i>CRHR1</i>	17 (43880047)	42.4% (A/G)	Intron	G

**Notes:** \*Additive model code 0, 1, 2 for risk allele; \*\*dominant model coded 0, 1 for the risk allele. Risk alleles counted were coded 0–6 from observed values 0–7, to normalize these data for analysis.

For additional specifications, see Boscarino et al.<sup>12</sup>

**Abbreviations:** PTSD, post-traumatic stress disorder; NYPRS, New York PTSD Risk Score; MAF, minor allele frequency.

#### Neuropsychiatric Disease and Treatment

Dovepress

### Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.